Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide
Corporate Update

waiting on 1854131,news,awp_editorial
waiting on 1854131,news,reuters8
waiting on 1854131,news,bloomberg9

   Kuros Biosciences AG / Key word(s): Annual Results
   Kuros Biosciences to Report Full Year Financial Results for 2023
   and Provide Corporate Update
   08.03.2024 / 07:00 CET/CEST
     ____________________________________________________________

   
   -    Company to host conference call and webcast on March 13,
   2024, at 3pm CET/10am US EST

   Schlieren (Zurich), Switzerland, March 8, 2024 - Kuros
   Biosciences ("Kuros" or "the Company"), a leader in
   next-generation bone graft technologies, today announced that it
   will report its full-year financial results and provide a
   corporate update on its business on March 13, 2024.  Following
   the announcement, the company will host a video conference call
   at 3pm CET/10am US EST to discuss the results.

To register for the video call, click here.

   For further information, please contact:
   Kuros Biosciences AG
   Daniel Geiger
   Chief Financial Officer
   t: +41 44 733 47 47
   e: daniel.geiger@kurosbio.com LifeSci Advisors
   Sandya von der Weid
   Investors
   t: +41 78 680 0538
   e: svonderweid@lifesciadvisors.com

   About Kuros Biosciences
   Kuros Biosciences is on a mission to discover, develop and
   deliver innovative biologic fusion technologies. With locations
   in the United States, Switzerland and the Netherlands, the
   company is listed on the SIX Swiss Exchange. The company's first
   commercial product, MagnetOsTM, is a unique advanced bone graft
   that has already been used across three continents and in 25,000
   fusion surgeries. For more information on the company, its
   products and pipeline, visit kurosbio.com.

____________________________________________________________

   End of Media Release
     ____________________________________________________________

   Language:    English
   Company:     Kuros Biosciences AG
                Wagistrasse 25
                8952 Schlieren
                Switzerland
   Phone:       +41 44 733 4747
   Fax:         +41 44 733 4740
   E-mail:      info@kurosbio.com
   Internet:    www.kurosbio.com
   ISIN:        CH0325814116
   Valor:       32581411
   Listed:      SIX Swiss Exchange
   EQS News ID: 1854131

   End of News EQS News Service
     ____________________________________________________________

1854131 08.03.2024 CET/CEST